To report the initial experience of patient-specific quality assurance (pQA) for the wobbling and line-scanning proton therapy at Samsung Medical Center.
Introduction
Since the introduction of proton beam therapy for medical use, the number of proton therapy facilities has been increasing worldwide. According to PTCOG (Particle Therapy Co-Operative Group) patient statistics, 1) over 170,000 patients have been treated by proton therapy from 1954 to 2017 and 79 facilities are in operation. Main reason for the increasing number of proton facilities is the dosimetric benefit of proton therapy which does not have an exit dose due to the characteristics of Bragg peaks. It opens a new way to save normal tissue by the reducing radiation dose to an area close to the target which would lower the risk of necrosis, mucositis, radiation pneumonitis, and secondary malignancy. 2, 3) It, however, should be aware of that proton therapy is very sensitive to uncertainty because of the sharp dose gradient at the distal region of the proton beam. The systematic uncertainties relevant to proton range include the inaccuracy of algorithm in dose computation, the uncertainty in the determination of stopping power from the computed tomography (CT) data, and daily machine status. 4) To verify whether the uncertainty is within the tolerance, patientspecific quality assurance (pQA) is necessary. It is a procedure delivering a dose with machine parameters identical to the patient treatment plan to ensure the consistency of a system and the accuracy of the delivered dose. The range, output, and two-dimensional dose distribution are verified by comparing the measurements with the treatment plan.
This work presents statistics and characteristics of the wobbling and the line-scanning pQA. Many institutions reported the result of pQA for the spot-scanning [5] [6] [7] [8] [9] but the pQA result of the wobbling and the line-scanning have not been reported yet. Even a majority of the proton treatments are shifted to the spot-scanning, there are users to have the wobbling and the line-scanning and this could help them by sharing the initial experience of pQA.
Materials and Methods

Proton therapy system at Samsung Medical Center
Proton therapy system (Sumitomo Heavy Industry, SHI, Japan) at Samsung Medical Center consisted of one cyclotron and two rotating gantries 10) ; one was equipped with a multipurpose nozzle for both capable of the wobbling and the line-scanning treatments and the other was a scanning dedicated nozzle only for the line-scanning treatment. The wobbling method 11, 12) was analogous to the double scatter-ing method of the IBA system. The initial pencil beam was rotated laterally along an elliptical track 11 times a second and let to pass a scatterer to form a blurred Gaussian beam, an example was given in Fig. 1 . The major and minor radius of the ellipse, hereafter referred to as a wobbling radius (WR), varied depending on energy and field size. The wobbling method had three categories of field size to optimize the wobbling radius: a "small" (diameter<11 cm), a "middle" (11 cm≤diameter<16 cm), and a "large"(diameter<16 cm). We did not use a large WR beam because more fineretuning was necessary to meet the accuracy required for clinical applications. Wobbling delivery method produced a spread-out Bragg peak (SOBP) by a ridge filters which was specifically designed to spread the proton energy from low to high with appropriate weights. The range of the proton beam was defined as the distal 90% of dose level and the SOBP width was defined as the length between points at distal 90% and at proximal 95% of dose level, which was normalized at mid SOBP. 
Patient statistics
In this work, the pQA results of 89 wobbling treatments and 44 line-scanning treatments were analyzed. A number of cancer types had been treated and the distribution of disease sites was shown in Table 1 . The patient data was collected from December 2015 to June 2016. For the wobbling method, the major treatment site was the liver, which accounted for half of the total treated fields. For the linescanning method, the main treatment site was Cranio-Spinal Irradiation (CSI) and its corresponding brain boost, above half (55.1%) of the total number of fields were included. Pediatric patients had the highest priority for proton therapy because the dosimetric superiority of proton CSI was well-known. 14) After that, head and neck cancer treatments made up 26.3% of the total fields. Only the linescanning method had been used for CSI treatments. For the wobbling method, 48.5% of the treatment fields were involved liver cancer, and 16.7% of the fields were for brain cancer.
QA items 1) QA items for the wobbling method
The pQA for the wobbling method verified the proton range, the width of SOBP. This guaranteed the proton en-ergy selection from the cyclotron, the correct selection of scatterer and ridge filter. The criterion for proton range tolerance was 1 mm. And it was 5 mm for the width of SOBP.
The proton range and the SOBP width were measured by ZEBRA (IBA, Belgium), a multi-layer ion chamber which has 2 mm spatial resolution.
2) QA items for the line-scanning method
For the line-scanning method, multiple proton energies were used to shape the three-dimensional dose distribution with intensity modulation. The best way to assure the accuracy of dose delivering was to measure a complete three-dimensional dose distribution and to compare it with the plan dose distribution. Currently, however, there is no way to perform it for routine pQA procedures due to the lack of a measurement method and time. As a practical solution, two-dimensional dose distributions at multiple depths were verified as other institutes reported. [5] [6] [7] [8] [9] For gamma analysis of the two-dimensional dose measurement, the passing rate tolerance was determined to be 95% with the 3%/3 mm criteria. 15) The two-dimensional dose distributions were measured by Octavius 729 XDR (PTW, Germany), an ion chamber array that has a 1 cm lateral resolution with a 24×24 cm 2 maximum measurable field size. 16, 17) For measurement, three depths were chosen manually which include a shallow depth (mainly 2 or 3 cm), middle depth (near the plan isocenter), and distal depth (2 or 3 cm deeper than middle depth). For the output measurement, a plane-parallel ionization chamber, PPC05 (IBA, Belgium) and PinPoint chamber (PTW31014, PTW, Freiburg, Germany) were used.
The absorbed dose is computed via TRS 398 protocol. 
Line-scanning method 1) Output difference
A total 44 plans and 118 treatment fields were analyzed.
The output difference presented in Fig. 3 www.ksmp.or.kr marked a blue circle for small field sizes (radius less than 11 cm) and a red asterisk for large field sizes (radius larger than 11 cm) in Fig. 3a, 3c . Both large and small field sizes did not give significant difference. The presence of a range shifter did not have any effect on the output difference, Fig.   3d where a plus symbol represented the output with range shifter and a diamond symbol represented those without a range shifter.
2) Two-dimensional dose distribution
The gamma passing rates for each field were represented as blue circles for the 3%/3 mm criterion in Fig. 4 . To see the effect of range shifter, a plus symbol represented the output with range shifter and a diamond symbol repre-sented those without a range shifter in Fig. 4 . The normalization of output was done at the middle depth, and the normalization factor was applied to the shallow and deep depth measurements to maintain the same three-dimensional dose scaling. At shallow, middle, and deep depths, every field passed the 3%/3 mm criterion. The passing rates were better at the middle depth than at those at shallow or deep depths. 
Discussion
Wobbling method
Line-scanning method
The average output difference was −0.69% with a standard deviation of 1.04%. The output difference did not depend on the presence of a range shifter, field size, energy, or modulation width. This small deviation was not only from the excellent beam modelling in TPS but from the daily output correction in the Treatment Control System (TCS). The daily output measurement was compared to a reference value and the deviation was registered as a correction factor in the TCS. The correction factor was applied for each treatment field in order to compensate the output fluctuation of the day. And, thanks to the output correction function in the TCS, the measured output deviation was compensated by the TCS for patient treatment. The actual output difference for each patient should be smaller than this result. At three depths, gamma passing rates with 3%/3 mm criterion were over 95% for every field. From the analysis of 188 scanning fields, we concluded that the beam delivery was within a tolerance and it was greatly matched with the dose computation in homogeneous medium.
Conclusion
The purpose of patient specific QA is to assess whether the delivered dose would be within the tolerance compared with the patient treatment plan. In addition, another important aspect is to verify that functioning of all integral parts of the treatment system specific to each treatment plan, e.g., a hardware status that includes the selection of the designated scatterer, a ridge filter, together with the scanning magnet performance. In addition, software status e.g. a transfer of treatment planning information via record and verify system, correct scanning pattern downloading and all integrated system software parameter specific to each treatment plan are required to be tested.
The result of pQA for the line-scanning cases was acceptable for patient treatment. For wobbling treatments, the range accuracy and the SOBP width were all acceptable. To enhance the dose computation accuracy, we have a plan to adopt Monte Carlo dose engine in the TPS for wobbling method.
